GLP-1 Therapies Newsletter
Issue #17December 29, 20257 studies

Among 6,700 obese patients, GLP-1s reduce heart surgery complications by 18%

GLP-1 drugs like Ozempic and Wegovy are proving to be much more than diabetes and weight loss medications. This week's research reveals surprising benefits for heart surgery patients and potential protection against neurodegeneration.

🫀 GLP-1 drugs slash heart surgery complications in obese patients

  • Among 6,700 obese patients undergoing atrial fibrillation ablation, those taking GLP-1 drugs had 18% fewer heart rhythm relapses compared to non-users (6.66% vs 7.72%)

  • GLP-1 users also had 27% lower risk of death and 20% fewer heart failure hospitalizations during 2-year follow-up

  • The benefits held even for patients without diabetes, suggesting the drugs' heart-protective effects go beyond blood sugar control

Why it matters: This real-world data from over 100 million patient records suggests GLP-1 drugs may become standard care before heart procedures, potentially preventing thousands of complications annually.

🥈 Top 2% journal 🔗 Circulation. Arrhythmia and electrophysiology Journal Article 🗓️ Dec 25

Key Findings

🧠 GLP-1 drugs may protect against Alzheimer's and Parkinson's

  • Clinical trials show GLP-1 drugs like liraglutide and lixisenatide can slow cognitive decline and motor symptoms in neurodegenerative diseases

  • The drugs appear to work by improving brain insulin signaling, reducing inflammation, and protecting neurons from damage

  • Japan is launching a major trial testing oral semaglutide in 99 Parkinson's patients to confirm disease-modifying effects

💡 These findings could transform how we think about preventing and treating brain diseases, not just metabolic ones.
🥈 Top 2% journal 🔗 Trends in molecular medicine Review 🗓️ Dec 24

💊 New oral GLP-1 pills show promise for diabetes and weight loss

  • Two new oral GLP-1 drugs (danuglipron and orforglipron) reduced blood sugar by 0.9-1.0% and caused 2-6 kg weight loss in 1,454 patients

  • Orforglipron was more effective for weight loss but both caused gastrointestinal side effects in many users

  • Oral formulations could make these treatments more accessible than current weekly injections

💡 Pill versions of GLP-1 drugs may overcome injection barriers and expand access to millions more patients.
🎖️ Top 10% journal 🔗 Frontiers in endocrinology Systematic Review 🗓️ Dec 26

⚡ GLP-1 drugs reduce insulin needs by 23% in type 1 diabetes

  • In 26-week study of type 1 diabetics using insulin pumps, semaglutide reduced total daily insulin by 22.6% compared to placebo

  • The effect was driven mainly by 30.5% reduction in mealtime insulin rather than background insulin

  • Early insulin reduction was due to direct drug effects, while later reductions came from weight loss

💡 This suggests GLP-1 drugs could help type 1 diabetics reduce their insulin burden while maintaining blood sugar control.
🥇 Top 1% journal 🔗 Diabetes care Journal Article 🗓️ Dec 22

🏥 Semaglutide cuts hospital stays by 10% in heart disease patients

  • Among 17,604 overweight patients with heart disease, those on semaglutide had 10% fewer hospital admissions over 3.5 years

  • Total hospital days were reduced by 11%, saving an average of 19 days per 100 patients annually

  • Benefits extended beyond heart-related admissions to all-cause hospitalizations

💡 The hospitalization benefits could significantly reduce healthcare costs and improve quality of life for millions of patients.
🥇 Top 1% journal 🔗 JAMA cardiology Journal Article 🗓️ Dec 23

🦴 GLP-1 drugs may increase fracture risk in older, severely obese patients

  • Analysis of 66,420 non-diabetic patients found 19% higher fracture risk with GLP-1 use (3.05% vs 2.61%)

  • Risk was concentrated in patients with BMI ≥40 and those over 68 years old, with fracture rates up to 9.3% in the oldest group

  • The mechanism may involve rapid weight loss affecting bone density or muscle mass

💡 Doctors may need to monitor bone health more closely in older, severely obese patients starting these medications.
Top 20% journal 🔗 The Journal of the American Academy of Orthopaedic Surgeons Journal Article 🗓️ Dec 22

💰 Income inequality limits access to life-saving diabetes drugs

  • Among 30.3 million Americans with type 2 diabetes, those with above-median income were 61% more likely to receive semaglutide

  • Private insurance increased access by 52% compared to other coverage types

  • The disparity affects those most at risk for diabetes complications - low-income and minority populations

💡 High drug costs are creating a two-tiered system where wealth determines access to breakthrough treatments.
Top 30% journal 🔗 International Journal for Quality in Health Care Journal Article 🗓️ Dec 24

Implications

GLP-1 drugs are emerging as a transformative class of medications with benefits far beyond their original diabetes indication. However, expanding access and understanding long-term effects - both positive and negative - will be crucial as these drugs reshape modern medicine.

Studies in this issue

Primary sources used for this newsletter.

  1. GLP-1 Receptor Agonist Treatment and Return of Irregular Heartbeats After Catheter Ablation in Obese Patients
    main storyCirculation. Arrhythmia and electrophysiology2025-12-25PMID 41446932
  2. Glucagon-Like Peptide-1 Drugs and Bone Fracture Risk in Overweight or Obese People Without Diabetes
    key findingThe Journal of the American Academy of Orthopaedic Surgeons2025-12-22PMID 41429015
  3. Semaglutide’s impact on lowering insulin doses in adults with type 1 diabetes and obesity using automated insulin pumps
    key findingDiabetes care2025-12-22PMID 41429002
  4. Semaglutide and Hospital Stay Rates in People with Obesity and Heart Disease
    key findingJAMA cardiology2025-12-23PMID 41433034
  5. Using GLP-1 drugs and multiple biomarkers to study brain degeneration
    key findingTrends in molecular medicine2025-12-24PMID 41444101
  6. Income Differences and Access to Semaglutide: Effects on Diabetes Care and Policy
    key findingInternational journal for quality in health care : journal of the International Society for Quality in Health Care2025-12-24PMID 41437637
  7. Effectiveness and safety of danuglipron and orforglipron in people with type 2 diabetes and obesity
    key findingFrontiers in endocrinology2025-12-26PMID 41450584

Continue reading

All GLP-1 Therapies issues